Search results for: Multi-Indication Medicines
Filter search results
New ISPOR Task Force Report on Multiple Criteria Decision Analysis
9 February 2016
…in Health. Professor Nancy Devlin, OHE’s Director of Research, co-chaired the ISPOR task force on uses of multiple criteria decision analysis (MCDA) in health care decision making. The first report…
Reconciling MCDA and Augmented Cost-Effectiveness Analysis: Do We Get the Same Decisions?
14 April 2021
…multicriteria decision analysis for valuing orphan medicines. Value in Health, 16(8), pp.1163-1169. Devlin N., Sussex J.: (2011). Incorporating Multiple Criteria in HTA – Methods and Processes. Office of Health Economics….
Multiple Sclerosis
10 January 1987
Multiple Sclerosis (MS) is a chronic disabling disease which attacks the central nervous system. It claims nearly a thousand lives a year in England and Wales and is responsible for…
Competition through Innovation, Innovation through Competition
1 November 1998
…policy debates that companies, in their pursuit of profits, are not investing in truly innovative medicines (Wastila et. al, 1989; Benzi, 1996). These industry critics ‘contend that profit incentives motivate…
Just Released: Health and the Use of Medicines in Wales
3 November 2011
…their medicines allocations, although the reasons remain unclear. At the same time, however, Wales lags behind England in the uptake of new primary and secondary care medicines that have received…
Comparing Prescription Medicines Prices in the UK to Prices in Other Countries
23 October 2012
…its most recent PPRS Report to Parliament, the Department of Health included the 250 top-selling branded medicines used in primary care in England in 2011; medicines used predominantly in the…
New OHE Consulting Report: Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?
16 February 2017
…to identify the most suitable approach for assessing regenerative medicines, but rather to test whether regenerative medicines could fit into the existing pathway developed for conventional medicines. We suggest a…
Health and the Use of Medicines in Primary Care in Wales
1 November 2011
…their medicines allocations, although the reasons remain unclear. At the same time, however, Wales lags behind England in the uptake of new primary and secondary care medicines that have received…
Economic Evaluation and Develop Medicines in the Development of Medicines
1 April 1988
…they give good value for money. Medicines have not been exempt from this process and there is increased emphasis on demonstrating additional benefit or social value from new medicines that…